Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) finds itself up over 15% going into Tuesday’s market close after the Company announced that Dr. John Laffey, a leading scholar in Acute Respiratory Distress Syndrome (ARDS) and the use of cutting-edge therapies to treat acute lung disorders, has been appointed to its ARDS Scientific Advisory Board (SAB), effective immediately.
Dr. Laffey joins a ARDS Scientific Advisory Board replete with noted colleagues, including Dr. Michael A. Matthay, Professor of Medicine and Anesthesia at the University of California at San Francisco (UCSF); Dr. Lorraine B. Ware, Professor of Medicine and Ralph and Lulu Owen Endowed Chair; and Dr. Perenlei Enkhbaatar, Charles Robert Allen Professor of Anesthesiology at The University of Texas Medical Branch.
Each member of the Board is a recognized key opinion leader with extensive clinical trial expertise in the treatment of acute lung disorders with Myron Holubiak, President and Chief Executive Officer of Citius, speaking highly of the Board’s newest addition, “Dr. Laffey is a highly accomplished and recognized expert in acute lung disorders. His cutting-edge research into the use of gene and stem cell-based therapies to treat ARDS will provide Citius with an important perspective as we explore the potential of this exciting new therapeutic area.”
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy.